Literature DB >> 1849761

Cytokine messenger RNA stability is enhanced in tumor cells.

H J Ross1, N Sato, Y Ueyama, H P Koeffler.   

Abstract

Hematopoietic growth factors are produced by a number of human tumors. We extracted RNA from selected human tumor cells known to produce at least one hematopoietic growth factor and found high levels of abnormally stable cytokine messenger (m)RNA. Half-life experiments performed after preventing RNA synthesis by exposing cells to actinomycin D before RNA extraction showed stabilization of cytokine messages in tumor cells in liquid culture as well as in human tumor xenografts grown in mice. Exposure to the phorbol ester phorbol 12-myristate 13-acetate (TPA) caused enhancement of granulocyte-macrophage colony-stimulating factor (GM-CSF) message level in lung cancer cells and in control fibroblasts but elevated levels persisted far longer in the tumor cells. In normal cells, an AU-rich sequence in the 3' untranslated region of cytokine mRNAs confers lability to the message. Although a beta-globin gene expression vector containing this region appears to produce unstable mRNA in lung cancer cells, cytokine mRNAs, which also contain this sequence, are very stable in the tumors we studied. This may indicate that another region of the cytokine mRNA molecule is of greater importance than the AU-rich region in determining mRNA stability in tumor cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849761

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Regulation of AUF1 expression via conserved alternatively spliced elements in the 3' untranslated region.

Authors:  G M Wilson; Y Sun; J Sellers; H Lu; N Penkar; G Dillard; G Brewer
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

Review 2.  MRNA stability and the control of gene expression: implications for human disease.

Authors:  Elysia M Hollams; Keith M Giles; Andrew M Thomson; Peter J Leedman
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

3.  Transcriptional and post-transcriptional regulation of interleukin-8.

Authors:  L H Villarete; D G Remick
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

4.  A cytokine mRNA-destabilizing element that is structurally and functionally distinct from A+U-rich elements.

Authors:  C Y Brown; C A Lagnado; G J Goodall
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

5.  Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.

Authors:  S Shetty; S Idell
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

Review 6.  Regulation of VIP gene expression in general. Human lung cancer cells in particular.

Authors:  A Davidson; T W Moody; I Gozes
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

7.  Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.

Authors:  D A Dixon; N D Tolley; P H King; L B Nabors; T M McIntyre; G A Zimmerman; S M Prescott
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

8.  Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.

Authors:  M R Young; G McCloskey; M A Wright; A S Pak
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

9.  Cyclosporin A promotes translational silencing of autocrine interleukin-3 via ribosome-associated deadenylation.

Authors:  A P Nair; H H Hirsch; M Colombi; C Moroni
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

10.  Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.

Authors:  M S Naylor; G W Stamp; W D Foulkes; D Eccles; F R Balkwill
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.